DNMT3A mutation

News alerts, weekly reports and conference planners

Entrez ID:

1788

Related biomarkers:

‹

DNMT3A amplification (1)

DNMT3A deletion (3)

DNMT3A amplification (1)

›

DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	venetoclax + sorafenib Resistant: C3 – Early Trials venetoclax + sorafenib Resistant : C3	venetoclax + sorafenib Resistant: C3 – Early Trials venetoclax + sorafenib Resistant : C3
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3	azacitidine Resistant: C3 – Early Trials azacitidine Resistant : C3
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
DNMT3A mutation	Chronic Myeloid Leukemia	DNMT3A mutation	Chronic Myeloid Leukemia	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3	YD312 Resistant: C3 – Early Trials YD312 Resistant : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	decitabine/cedazuridine Sensitive: C3 – Early Trials decitabine / cedazuridine Sensitive : C3	decitabine/cedazuridine Sensitive: C3 – Early Trials decitabine / cedazuridine Sensitive : C3
DNMT3A mutation	Colorectal Cancer	DNMT3A mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
DNMT3A mutation	T Cell Non-Hodgkin Lymphoma	DNMT3A mutation	T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3
DNMT3A mutation	Non Small Cell Lung Cancer	DNMT3A mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	RVU120 Sensitive: C3 – Early Trials RVU120 Sensitive : C3	RVU120 Sensitive: C3 – Early Trials RVU120 Sensitive : C3
DNMT3A mutation	Peripheral T-cell Lymphoma	DNMT3A mutation	Peripheral T-cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3
DNMT3A mutation	Peripheral T-cell Lymphoma	DNMT3A mutation	Peripheral T-cell Lymphoma	azacitidine oral Resistant: C3 – Early Trials azacitidine oral Resistant : C3	azacitidine oral Resistant: C3 – Early Trials azacitidine oral Resistant : C3
DNMT3A mutation	Lymphoma	DNMT3A mutation	Lymphoma	azacitidine + romidepsin Sensitive: C3 – Early Trials azacitidine + romidepsin Sensitive : C3	azacitidine + romidepsin Sensitive: C3 – Early Trials azacitidine + romidepsin Sensitive : C3
DNMT3A mutation	Triple Negative Breast Cancer	DNMT3A mutation	Triple Negative Breast Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4	RVU120 Sensitive: C4 – Case Studies RVU120 Sensitive : C4
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D	EPZ-5676 Sensitive: D – Preclinical EPZ-5676 Sensitive : D
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D	ABBV-744 Sensitive: D – Preclinical ABBV-744 Sensitive : D
DNMT3A mutation	Acute Lymphocytic Leukemia	DNMT3A mutation	Acute Lymphocytic Leukemia	PC-002 Sensitive: D – Preclinical PC-002 Sensitive : D	PC-002 Sensitive: D – Preclinical PC-002 Sensitive : D

DNMT3A mutation

Associations